CD8A and classic Hodgkin lymphoma: Thus, by ex‐vivo analysis, we observed modest differences in CD8+ T cell responses against relevant EBV latency‐II proteins between HLA‐A*02+ and to HLA‐A*02– patients with EBV+cHL.